Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 3, 2011, Pages 292-296

  Brunello, Antonella ^a   Kapoor, Rachna ^b   Extermann, Martine ^b  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

chemotherapy; elderly; hyperglycemia; non Hodgkin lymphoma; outcomes; prostate cancer; toxicity

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GLUCOSE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ABSCESS; ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELLULITIS; CHEMOTHERAPY INDUCED EMESIS; CONGESTIVE HEART FAILURE; CORTICOSTEROID THERAPY; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG FEVER; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FISTULA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GLUCOSE BLOOD LEVEL; HEART ARRHYTHMIA; HOSPITAL ADMISSION; HUMAN; HYPERGLYCEMIA; INTESTINE ISCHEMIA; KIDNEY FAILURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PAIN; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SEPSIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; URINARY TRACT HEMORRHAGE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD GLUCOSE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLORIDA; HUMANS; HYPERGLYCEMIA; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; LYMPHOMA, NON-HODGKIN; MALE; MEDICAL RECORDS; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME; VINCRISTINE;

EID: 79958255982     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181e1d0c0     Document Type: Article

References (41)

1. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653. (Pubitemid 41817713)
2. Pittas AG, Siegel RD, Lau J. Insulin therapy and in-hospital mortality in critically ill patients: systematic review and meta-analysis of randomized controlled trials. J Parenter Enteral Nutr. 2006;30:164-172. (Pubitemid 44314790)
3. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345:1359-1367.
4. van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449-461. (Pubitemid 43200296)
5. Weiser MA, Cabanillas ME, Konopleva M, et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer. 2004;100:1179-1185. (Pubitemid 38325945)
6. Meyerhardt JA, Catalano PJ, Haller DG, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2003;21:433-440. (Pubitemid 46606471)
7. Coughlin SS, Calle EE, Patel AV, et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159: 1160-1167. (Pubitemid 38747263)
8. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359. (Pubitemid 34251969)
9. Good RA. Evaluation of the evidence for immune surveillance. In: Smith RT, Landy M, eds. Immune Surveillance. New York, NY: Academic Press; 1970.
10. Reedy J. Galen on cancer and related diseases. Clio Med. 1975;10:227-238.
11. Freund E. Zur diagnose des carcinoms. Wien Med Blätter. 1885;8:267.
12. Glicksman AS, Myers WPL, Rawson RW. Diabetes mellitus and carbohydrate metabolism in patients with cancer. Med Clin North Am. 1956;40:887-900.
13. Dankner R, Chetrit A, Segal P. Glucose tolerance status and 20 year cancer incidence. Isr Med Assoc J. 2007;9:592-596. (Pubitemid 47323414)
14. Stattin P, Bjor O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care. 2007;30:561-567. (Pubitemid 46354334)
15. Ali NA, O'Brien JM Jr, Blum W, et al. Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality. Cancer. 2007;110:96-102. (Pubitemid 46986422)
16. Boyd DH, Clapp B, Finnegan M. The intravenous glucose tolerance test in malignant disease. Br J Cancer. 1962;16:577-582.
17. National Cancer Institute Common Toxicity Criteria for Adverse Events v3.0 (CTCAE) 2003, published 2006. Available at: http://ctep.info.nih.gov/ protocol Development/electronic-applications/docs/ctcaev3.pdf. Accessed November 14, 2009.
18. Attili VS, Bapsy PP, Dadhich HK, et al. Impact of diabetes on cancer chemotherapy outcome: a retrospective analysis. Int J Diabetes Dev Ctries-serial online-. 2007;27:122-128. Available at: http://www.ijddc.com/text. asp?2007/27/4/122/38631.
19. Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992;41:237-248.
20. Hsieh FY, Block DA, Larsen MD. A simple method of sample size calculation for linear and logistic regression. Stat Med. 1998;17:1623-1634. (Pubitemid 28367842)
21. Folstein MF, Folstein SE, Mc Hugh PR. A Mini mental state: a practical method for grading the cognitive status of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
22. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1983;17:37-49. (Pubitemid 13123113)
23. Cheraskin E, Ringsdorf WM Jr, Hutchins K, et al. Effect of diet upon radiation response in cervical carcinoma of the uterus. Acta Cytol. 1968;12:433-438.
24. Ellis ME, Weiss RB, Korzun AH, et al. Hyperglycemic complications associated with adjuvant chemotherapy of breast cancer: a cancer and leukemia group B (CALGB) study. Am J Clin Oncol. 1986;9:533-536. (Pubitemid 17205985)
25. Sonabend RY, McKay SV, Okcu MF, et al. Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia. J Pediatr. 2009;155:73-78.
26. Turturro F, Von Burton G, Friday E. Hyperglycemia-induced thioredoxininteracting protein expression differs in breast cancer-derived cells and regulates paclitaxel IC50. Clin Cancer Res. 2007;13:3724-3730. (Pubitemid 46955137)
27. Derr RL, Ye X, Islas MU, et al. Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009;27:1082-1086.
28. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242. (Pubitemid 34438862)
29. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512. (Pubitemid 39315317)
30. Extermann M, Bonetti M, Sledge GW, et al. MAX2-a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials. Eur J Cancer. 2004;40:1193-1198. (Pubitemid 38526338)
31. Houterman S, Janssen-Heijnen ML, Verheij CD, et al. Greater influence of age than co-morbidity on primary treatment and complications of prostate cancer patients: an in-depth population-based study. Prostate Cancer Prostatic Dis. 2006;9:179-184. (Pubitemid 43970968)
32. Freyer G, Geay JF, Touzet S, et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol. 2005;16:1795-1800. (Pubitemid 41631242)
33. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995;122:321-326.
34. Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002;20:42-51. (Pubitemid 34032594)
35. Hammarsten J, Hogstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer. 2005;41:2887-2895. (Pubitemid 41713128)
36. Extermann M, Chen H, Cantor AB, et al. Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study. Eur J Cancer. 2002;38:1466-1473. (Pubitemid 34756399)
37. Sparreboom A, Wolff AC, Mathijssen RH, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol. 2007;25:4707-4713. (Pubitemid 350086471)
38. Lin LY, Lin HC, Lee PC, et al. Hyperglycemia correlates with outcomes in patients receiving total parenteral nutrition. Am J Med Sci. 2007;333:261-265.
39. Vanhorebeek I, Ingels C, Van den Berghe G. Intensive insulin therapy in high-risk cardiac surgery patients: evidence from the Leuven randomized study. Semin Thorac Cardiovasc Surg. 2006;18:309-316. (Pubitemid 46464510)
40. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. Diabetes Care. 1998;21:518-524.
41. Yancik R, Ries L. Aging and cancer in America: demographic and epidemiologic perspectives. Hematol Oncol Clin North Am. 2000;14:17-23. (Pubitemid 30078429)